Bora Wins Prestigious CDMO Leadership Awards TAIPEI, TAIWAN, March 20, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today celebrated winning three Outsourced Pharma Leadership Awards: Best New or Transformed CDMO, Biologics - Global, and Small Molecule Dosage Form - Global. The awards were presented at a...
Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer TAIPEI, TAIWAN – January 9th, 2025 – Bora Biologics, a fast-growing division of leading contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, today announced that it will support DotBio, a Singaporean biopharmaceutical company...
Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan Taipei, Taiwan (January 6, 2025) – Bora Pharmaceuticals Co., Ltd. (“Bora,” TWSE: 6472), a global cGMP contract development and manufacturing organization (CDMO), is pleased to announce the grand unveiling of its new small molecule dose form facility in Zhongli, Taiwan. This represents another...
Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A Ceremony: "Deal of the Year" Award and "Best Cross-Border M&A" Award December 11, 2024 —The Taiwan Mergers & Acquisition and Private Equity Council announced its winners today in the MAPECT Award Ceremony. Among 149 M&A cases, Bora Pharmaceuticals distinguished itself by winning both the "Deal of the Year”...